Weight Loss Treatment – Mounjaro 10mg – Step 4 – £201.49

What is it?

Mounjaro is a prescription medication administered via self-injection to assist with weight management. It contains tirzepatide, a peptide that helps control blood sugar levels and energy balance, reducing hunger and cravings. By influencing certain brain pathways, it promotes a sense of fullness, helping individuals stay satisfied for longer and experience less appetite. When paired with a calorie-controlled diet and regular physical activity, it can lead to notable weight loss. Research has shown that Mounjaro supports weight loss beyond what diet and exercise alone can achieve.

Who is Mounjaro for?

Ingredients:

Each 10 mg dose contains tirzepatide (10 mg in 0.6 mL solution), along with sodium phosphate dibasic heptahydrate, sodium chloride, concentrated hydrochloric acid, sodium hydroxide (for pH adjustment), and water for injection.

Administration Guidelines:

Before starting this treatment, carefully read the instructions for use (IFU) for proper administration guidance. It can be taken at any time of day, with or without food. Suitable injection sites include the abdomen, thigh, or upper arm – be sure to rotate sites with each dose. Always inspect the solution visually before use; it should be clear and colourless to slightly yellow. Do not use the medication if the solution appears discoloured or contains particles.

Contraindications:

It is contraindicated in patients with:

• – A personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2.
• – Known hypersensitivity to tirzepatide or any of its excipients.

Precautions and Warnings:

– Injection Site: Injection must be administered in the abdomen, thigh, or upper arm. The injection site and timing may vary without requiring dose adjustments.

– Missed Dose: If a dose is missed and it has been no longer than 4 days, administer the missed dose as soon as possible and proceed with the next scheduled dose. If more than 4 days have passed, skip the missed dose and continue with the regular dosing schedule.

– Change of Injection Day: The day for weekly administration can be adjusted, provided there is a minimum of 3 days between two doses. (≥72 hours).

– Storage: Store the medication in a refrigerator (2°C – 8°C). Do not freeze. Keep it in its original packaging to shield it from light. It may be stored at room temperature, not exceeding 30°C, for up to 21 cumulative days. After this period, the pre-filled pen must be discarded.

– Acute Pancreatitis Risk: Caution is advised for patients with a history of pancreatitis. Stop using it if symptoms of pancreatitis occur.

– Hypoglycemia Risk in Type 2 Diabetes: Monitor for hypoglycemia when using Mounjaro in combination with insulin or insulin secretagogues. Dose adjustments of insulin or other medications may be necessary.

– Gastrointestinal Disorders: For patients with severe gastrointestinal conditions, such as gastroparesis, use it with caution.

– Diabetic Retinopathy: Exercise caution in patients with diabetic retinopathy and ensure appropriate monitoring.

– Pregnancy and Lactation: Mounjaro is not recommended for use during pregnancy due to limited available data. It is also unknown whether the medication is excreted in human breast milk, so the potential risks should be weighed carefully against the benefits.

– Effects on Driving and Operating Machinery: It is unlikely to impair the ability to drive or operate machinery, but caution is advised when used with insulin or sulfonylurea to prevent hypoglycemia.

Adverse Effects: Potential side effects can include, but are not limited to: 

• – Very Common: Hypersensitivity reactions, hypoglycemia (especially with insulin or sulfonylureas), and dizziness.
• – Common: Nausea, diarrhoea, vomiting, constipation, and fatigue.
• – Uncommon: Hair loss, abdominal pain, and acute pancreatitis.

For a complete list of potential side effects, please consult your healthcare provider.

*Note:

• – (1) Dose-dependent
• – (2) More common in certain populations
• – Fatigue may encompass both general exhaustion and physical weakness.